MaaT Pharma
Develops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments.
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 47 % | 56 % | 44 % | 171 % | 256 % | 36 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (882 %) | (916 %) | (828 %) | (819 %) | (260 %) | 30 % | 43 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (928 %) | (959 %) | (885 %) | (899 %) | (297 %) | (25 %) | 13 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 941 % | 1012 % | 943 % | 854 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
MaaT Pharma is a clinical-stage company specializing in microbiome restoration therapies aimed at treating life-threatening diseases, particularly in the field of oncology. The company leverages its advanced MMRB integrated platform to develop biotherapeutics that restore microbiome function. MaaT Pharma's business model focuses on strategic partnerships to accelerate drug access to patients, enhancing the preparation and execution of clinical trials. The company generates revenue through the development and commercialization of its microbiome biotherapeutics, with a strong emphasis on collaboration with investigator-initiated studies to gather Big Data using its metagenomics platform. MaaT Pharma serves patients suffering from severe conditions like intestinal acute Graft versus Host Disease, positioning itself as a leader in the microbiome clinical pipeline.
Keywords: microbiome, oncology, biotherapeutics, clinical-stage, partnerships, MMRB platform, Graft versus Host Disease, metagenomics, drug access, pipeline.